STOCK TITAN

Jounce Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Jounce Therapeutics (NASDAQ: JNCE) will participate in two upcoming investor conferences. The H.C. Wainwright Global Investment Conference will feature an on-demand presentation available starting May 24, 2022, at 7:00 a.m. ET. The Cowen’s 3rd Annual Oncology Innovation Summit will include a live presentation on June 2, 2022, at 1:30 p.m. ET. Webcasts of both events can be accessed on Jounce's website, with replays available for 30 days post-event. Jounce focuses on developing cancer immunotherapies and is advancing multiple clinical programs.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate at the following upcoming investor conferences:

  • H.C. Wainwright Global Investment Conference: Presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.
  • Cowen’s 3rd Annual Oncology Innovation Summit: Insights for ASCO & EHA: A live presentation will take place virtually on Thursday, June 2, 2022 at 1:30 p.m. ET.

A webcast of each presentation can be accessed by visiting the Investors & Media section of Jounce’ website at https://ir.jouncetx.com/investor-overview. A replay of each webcast will be archived on Jounce’s site for 30 days following the event.

About Jounce Therapeutics:

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. JTX-8064 is currently being investigated alone and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, in one monotherapy and seven indication-specific combination therapy cohorts in the Phase 1/2 INNATE trial and is currently enrolling patients with advanced solid tumors in the Phase 2 portion of the study. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to GS-1811 (formerly JTX-1811), a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Investor and Media Contact:
Eric Laub
+1-857-259-3853
elaub@jouncetx.com


FAQ

What will Jounce Therapeutics present at the H.C. Wainwright Global Investment Conference?

Jounce will have an on-demand presentation available from May 24, 2022, at 7:00 a.m. ET.

When is Jounce Therapeutics' live presentation at Cowen’s Oncology Innovation Summit?

The live presentation will take place on June 2, 2022, at 1:30 p.m. ET.

How can I access the Jounce Therapeutics presentations?

Webcasts of the presentations can be accessed on Jounce's website, with replays available for 30 days.

What is the focus of Jounce Therapeutics?

Jounce Therapeutics is focused on developing novel cancer immunotherapies and predictive biomarkers.

What is Jounce's highest priority program?

Jounce's highest priority program is JTX-8064, a LILRB2 receptor antagonist aimed at reprogramming immune-suppressive tumor-associated macrophages.

JNCE

NASDAQ:JNCE

JNCE Rankings

JNCE Latest News

JNCE Stock Data

44.39M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge